JARDIANCE®
Empagliflozin
Indications
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Resources
Browse our engaging and informative collection of resources to learn more about JARDIANCE® (empagliflozin) for chronic kidney disease.
Downloadable resource
JARDIANCE Initiation & Management guide for T2D, CHF and CKD
Downloadable resource
JARDIANCE CKD patient booklet
PC-GB-108945 V3
April 2024